CHA ÀÇ°úÇдëÇб³ Â÷º´¿ø professor

±³¼ö´Ô»çÁø
  • ¼Û¿µ½Å
  • ¼Ò ¼Ó: ºÐ´çÂ÷º´¿ø
  • Àü¹®ºÐ¾ß : °©»ó¼±Áúȯ/´ç´¢º´/±âŸ ³»ºÐºñ ´ë»çÁúȯ
  • Á÷ À§: Á¶±³¼ö
  • ¸Þ ÀÏ: ºñ°ø°³
  • Àü È­: 1577-4488
  • ÆÑ ½º:
  • ÁÖ ¼Ò: °æ±âµµ ¼º³²½Ã ºÐ´ç±¸ ¾ßžµ¿ 351¹øÁö
  • ȨÆäÀÌÁö:
  • ·Î±×ÀÎ

ÅǸ޴º

ÁÖ¿ä¹ßÇ¥³í¹®

ÁÖ¿ä¹ßÇ¥³í¹®
¹øÈ£ ±¸ºÐ Á¦¸ñ
159 (±¹¿Ü)SCI Effectiveness of low-intensity atorvastatin 5 mg and ezetimibe 10 mg combination therapy compared with moderate-intensity atorvastatin 10 mg monotherapy: A randomized, double-blinded, multi-center, phase III study
158 (±¹¿Ü)SCI A cohort study found a high risk of end-stage kidney disease associated with acromegaly
157 (±¹¿Ü)SCI Different Molecular Phenotypes of Progression in BRAFandRAS-Like Papillary Thyroid Carcinoma
156 (±¹¿Ü)SCI Thyroid Dysfunction After Atezolizumab and Bevacizumab is Associated with Favorable Outcomes in Hepatocellular Carcinoma
155 (±¹¿Ü)±âŸ Trends in Prevalence of Hypertriglyceridemia and Related Factors in Korean Adults: A Serial Cross-Sectional Study
154 (±¹¿Ü)SCI Efficacy and safety of monotherapy with enavogliflozinin Korean patients with type 2 diabetes mellitus: Resultsof a 12-week, multicentre, randomized, double-blind,placebo-controlled, phase 2 trial
153 (±¹¿Ü)SCI Efficacy and safety of enavogliflozin, a novel SGLT2 inhibitor, in Korean people with type 2 diabetes: A 24-week, multicentre, randomized, double-blind, placebo-controlled, phase III trial
152 (±¹¿Ü)SCI Efficacy and safety of enavogliflozin added to metformin plus gemigliptin treatment in patients with type 2 diabetes: a double-blind, randomised study with dapagliflozin as a comparator: ENHANCE-D study
151 (±¹¿Ü)SCI Fatty Liver & Diabetes Statistics in Korea: Nationwide Data 2009 to 2017
150 (±¹¿Ü)SCI Prolonged Use of Carnitine-Orotate Complex (Godex¢ç) Is Associated with Improved Mortality: A Nationwide Cohort Study
ÀÌÀüÆäÀÌÁö À̵¿ 1 2 3 4 5 6 7 8 9 10 ´ÙÀ½ÆäÀÌÁö À̵¿
Copyright ¨Ï chamc, All rights reserved.

ºü¸£°í Æí¸®ÇÑ ÀÎÅÍ³Ý Áø·á¿¹¾à

  • °­³²Â÷º´¿ø
  • ºÐ´çÂ÷º´¿ø
  • ºÐ´çÂ÷¿©¼ºº´¿ø
  • ±¸¹ÌÂ÷º´¿ø
  • ¿©¼ºÀÇÇבּ¸¼Ò
  • Â÷¿ò

ÀüÈ­¹®ÀÇ

  • °­³²Â÷º´¿ø 02.3468.3000
  • ºÐ´çÂ÷º´¿ø 031.780.5000
  • Â÷¿ò 02.3015.5300
  • ±¸¹ÌÂ÷º´¿ø 054.450.9700
  • ´ë±¸¿©¼ºÂ÷º´¿ø 02.222.4200
  • °­³²°ÇÁø¼¾ÅÍ 02.2191.3900
  • ºÐ´çÁ¾ÇÕ°Ç°­ÁõÁø¼¾ÅÍ 031.780.5940
  • ½ºÆ÷·º½º °ÇÁø¼¾ÅÍ 02.3473.2111
  • ±¸¹ÌÂ÷º´¿ø°ÇÁø¼¾ÅÍ 054.450.9800
  • ȨÆäÀÌÁö°ü¸®ÀÚ 031.780.1729